According to Amicus Therapeutics 's latest financial reports the company's current revenue (TTM) is $0.39 B. In 2022 the company made a revenue of $0.32 B an increase over the years 2021 revenue that were of $0.30 B.The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Year | Revenue | Change |
---|---|---|
2023 (TTM) | $0.39 B | 21.3% |
2022 | $0.32 B | 7.76% |
2021 | $0.30 B | 17.11% |
2020 | $0.26 B | 43.16% |
2019 | $0.18 B | 99.72% |
2018 | $91.24 M | 147.08% |
2017 | $36.93 M | 644.86% |
2016 | $4.95 M | |
2015 | N/A | -100% |
2014 | $1.22 M | 237.19% |
2013 | $0.36 M | -98.03% |
2012 | $18.41 M | -14.1% |
2011 | $21.43 M | 2224.73% |
2010 | $0.92 M | -98.57% |
2009 | $64.35 M | 330.04% |
2008 | $14.96 M |
Company | Revenue | Revenue differencediff. | Country |
---|---|---|---|
Novo Nordisk NVO | $33.81 B | 8,367.11% | ๐ฉ๐ฐ Denmark |
Biogen BIIB | $9.83 B | 2,362.87% | ๐บ๐ธ USA |
GlaxoSmithKline GSK | $37.84 B | 9,377.52% | ๐ฌ๐ง UK |
Lexicon Pharmaceuticals
LXRX | $1.2 M | -99.70% | ๐บ๐ธ USA |
Esperion Therapeutics ESPR | $0.11 B | -70.87% | ๐บ๐ธ USA |
BioMarin Pharmaceutical BMRN | $2.41 B | 505.78% | ๐บ๐ธ USA |